chufangao/CTO huggingface dataset:
Clinical trial NCT04970719: Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus
Official title: The Efficacy of Baricitinib Plus Remdesivir Compared to Dexamethasone Plus Remdesivir in Hospitalised COVID-19 Patients With Diabetes Mellitus
Sponsor: Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: adequate cases were not available
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-10
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Plan to share individual participant data: YES
IPD sharing description: all IPD that underlie results in a publication
IPD time frame: relative to the time when summary data are published
IPD access criteria: all data will be available if required
Clinical trial NCT05625347: Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function
Official title: A Single-dose, Open-label, Multi-center, Randomized, 2-treatment Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function
Sponsor: Vectura, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The pivotal study failed to meet the primary endpoint. Without a successful readout of the pivotal study, there was no longer a purpose for the supportive BORA-1A-C302 study.
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-03-11
Primary completion date: 2023-06-30
Completion date: 2023-06-30
Plan to share individual participant data: NO
Clinical trial NCT01738243: Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease
Official title: Phase IV Study of Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease
Acronym: HALR
Sponsor: University of California, Los Angeles (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: recruitment challenges
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-12-31
Primary completion date: 2021-09-30
Completion date: 2021-09-30
Clinical trial NCT03364491: Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean
Official title: Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial
Acronym: TXA
Sponsor: The George Washington University Biostatistics Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 11000.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-15
Primary completion date: 2021-07-24
Completion date: 2021-10-29
Baseline population: Of 5529 participants, 4 were enrolled in the study for a second pregnancy in the tranexamic acid group and out of 5471 participants, 1 was enrolled for a second pregnancy in the placebo group. Only the first pregnancy was included in the analysis.
Plan to share individual participant data: YES
IPD sharing description: The dataset will be shared per NIH policy after the completion and publication of the main analyses. Data be will accessible through the NICHD Data and Specimen Hub.
Clinical trial NCT04088786: Phase I Trial HIPEC With Nal-irinotecan
Official title: Phase I Trial of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy With Nanoliposomal Irinotecan in Patients With Peritoneal Surface Malignancies
Sponsor: Stony Brook University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-22
Primary completion date: 2021-10-11
Completion date: 2022-04-14
Plan to share individual participant data: NO
Clinical trial NCT03017508: Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder
Official title: Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-01-31
Primary completion date: 2019-12-31
Completion date: 2021-01-29
Plan to share individual participant data: NO
Clinical trial NCT05413187: A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder
Official title: A Double-Blind, Placebo Controlled, Randomized Trial to Assess the Efficacy and Safety of Medical Grade Cannabis (MGC) in Children Diagnosed With Autism Spectrum Disorder
Sponsor: TO Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: withdrawn due to COVID-19
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-01
Primary completion date: 2022-09-01
Completion date: 2022-09-01
Plan to share individual participant data: NO
Clinical trial NCT03529929: Glucocorticoid Inflammation Paradox in Human Skeletal Muscle
Official title: Glucocorticoid Inflammation Paradox in Human Skeletal Muscle
Sponsor: Texas A&M University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: withdrawn
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-01
Primary completion date: 2020-05-01
Completion date: 2020-12-01
Plan to share individual participant data: NO
Clinical trial NCT02447991: Rizatriptan for Episodic Dizziness in Vestibular Migraine
Official title: A Phase II/III Trial on Rizatriptan for Vestibular Migraine
Sponsor: University of California, Los Angeles (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 223.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-12-31
Primary completion date: 2020-07-31
Completion date: 2020-07-31
Clinical trial NCT04052061: QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
Official title: Open-Label, Phase 1 Study of CD19 t-haNK In Subjects With Diffuse Large B-Cell Lymphoma Who Have Received 2 Or More Lines of Therapy And Are Ineligible For Transplant
Sponsor: ImmunityBio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Trial not initiated
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-16
Primary completion date: 2023-09-18
Completion date: 2023-12-18
Plan to share individual participant data: NO
Clinical trial NCT04059458: Mandibular Furcation III Regeneration (FURC-III-REGEN)
Official title: Biphasic Calcium Phosphate and a Collagen Membrane or Biphasic Calcium Phosphate and Enamel Matrix Proteins, in the Regenerative Treatment of Furcation Grade III Defects
Acronym: FURC-III-REGEN
Sponsor: University of Oslo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Recruitment problem
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-15
Primary completion date: 2023-11-27
Completion date: 2023-11-27
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03861403: A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Official title: A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Sponsor: Leap Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Product development discontinued unrelated to safety.
Enrollment: 10.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-05-20
Primary completion date: 2020-07-14
Completion date: 2020-07-14
Clinical trial NCT03229538: STeroids to REduce Systemic Inflammation After Infant Heart Surgery
Official title: STeroids to REduce Systemic Inflammation After Infant Heart Surgery (STRESS)
Acronym: STRESS
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1263.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-18
Primary completion date: 2022-03-31
Completion date: 2022-03-31
Plan to share individual participant data: YES
IPD sharing description: The investigators will disseminate findings through publications, national presentations, participation in the CTSA Consortium, the CTSA website and via the existing infrastructure of the Society of Thoracic Surgeons Congenital Heart Surgery Database. Data collection supported by CTSA funds will follow the principles outlined in the Final NIH Statement on Sharing Research Data. Participating institutions will honor the principle that data sharing is critical for expeditious translation of research findings to the improvement of human health. The investigators abide strictly by the provisions of the Health Insurance Portability and Accountability Act (HIPAA). The investigators will continue to use traditional venues for data sharing, such as publications in leading scientific journals and deposit all applicable NIH-funded research results to PubMed Central in compliance with the NIH's Public Access Policy.
Clinical trial NCT03111212: Iloprost in Acute Respiratory Distress Syndrome
Official title: Therapeutic Iloprost for the Treatment of Acute Respiratory Distress Syndrome (ARDS) (the ThIlo-Trial)
Acronym: ThIlo
Sponsor: University Hospital Tuebingen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 150.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-25
Primary completion date: 2021-05-14
Completion date: 2021-08-14
Plan to share individual participant data: UNDECIDED
Clinical trial NCT01470612: Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis
Official title: A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Acronym: OCTAVE
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 944.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-10-01
Primary completion date: 2020-08-06
Completion date: 2020-08-06
Baseline population: Full analysis set (FAS) included all participants who received at least 1 dose of study medication in this study.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04665375: Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?
Official title: Can the Weight Gain Associated With Use of Integrase Strand Inhibitors be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF in Patients Living With HIV? (DeLiTE)
Acronym: DeLiTE
Sponsor: University Health Network, Toronto (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: enrollment futility
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-26
Primary completion date: 2024-03-31
Completion date: 2024-03-31
Plan to share individual participant data: NO
Clinical trial NCT03017547: A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Preliminary Efficacy Study of IC14 in Acute Respiratory Distress Syndrome
Sponsor: Implicit Bioscience (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: seeking funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-30
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Clinical trial NCT05438498: Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
Official title: Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 Infection in Immuno-Suppressed Cancer Patients
Sponsor: MediMergent, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: FDA withdrew EUA for AZD7442
Enrollment: 550.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-06-03
Primary completion date: 2023-04-29
Completion date: 2023-06-30
Clinical trial NCT03809039: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects
Official title: A Randomised, Double-Blind, Placebo-Controlled Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of MT-6345 in Healthy Subjects
Sponsor: Mitsubishi Tanabe Pharma America Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Preclinical finding
Enrollment: 52.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-15
Primary completion date: 2019-07-01
Completion date: 2020-07-01
Baseline population: The analysis population is the subjects of Part 1 and Part 3 since the subjects of part 2 were selected from part 1.
Plan to share individual participant data: NO
Clinical trial NCT01950234: ACTH in Progressive Forms of MS
Official title: Treatment of Progressive Forms of Multiple Sclerosis With Pulsed ACTH (Acthar Gel)
Sponsor: University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The funding source discontinued financial support for the study.
Enrollment: 59.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-04-17
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Clinical trial NCT04434001: ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery
Official title: ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery Randomized Controlled Pilot Phase II Study
Acronym: ZEPLAST-PED
Sponsor: IRCCS Policlinico S. Donato (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study encountered unexpected difficulties in enrolling patients due to requirements for the Informed Consent. 60% of our patients comes from abroad with only one accompanying parent. The rules of our EC require both parents to sign the consent.
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-27
Primary completion date: 2021-05-31
Completion date: 2021-06-30
Plan to share individual participant data: NO
Clinical trial NCT03334253: Low-Dose Atropine for Treatment of Myopia
Official title: Low-Dose Atropine for Treatment of Myopia (Myopia Treatment Study)
Acronym: MTS1
Sponsor: Jaeb Center for Health Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 200.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-01
Primary completion date: 2022-04-15
Completion date: 2022-09-12
Plan to share individual participant data: YES
IPD sharing description: In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.
IPD time frame: After completion of the protocol and publication of the primary manuscript, the data will be made available for the duration of the grant and any future grants.
IPD access criteria: Users accessing the data must enter an email address.
Clinical trial NCT02502747: RIGENERA 2.0 Trial
Official title: RIGENERA 2.0 (Recupero Dall'Infarto Miocardico Con G-CSF E Nuovi Esempi di Rigenerazione Avanzata) Project: The Combined Effect of Subcutaneous Granulocyte - Colony Stimulating Factor and Myocardial Contrast Echocardiography With Intravenous Infusion of Sulphur Hexafluoride on Post-infarction Left Ventricular Function
Acronym: RIGENERA
Sponsor: Catholic University of the Sacred Heart (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: slow enrolment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-31
Primary completion date: 2021-10-31
Completion date: 2021-12-31
Clinical trial NCT05435053: Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
Official title: Irreversible Electroporation in Combination With Immune Checkpoint Inhibition, in Patients With Metastatic Pancreatic Cancer - A Prospective, Phase 2 Study
Acronym: CHECKPOINT
Sponsor: Zealand University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated on the basis on an evaluation of the safety and efficacy of the 9 included patients of which 2 of the patients were excluded before receiving any study treatments, thus 7 patients were treated in the study.
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-09-08
Primary completion date: 2023-08-30
Completion date: 2023-08-30
Plan to share individual participant data: NO
Clinical trial NCT04583969: ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19
Official title: A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 527.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-23
Primary completion date: 2022-04-22
Completion date: 2022-04-22
Baseline population: The intention-to-treat (ITT) population includes all randomized participants.
Clinical trial NCT04242147: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Official title: A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor's decision.
Enrollment: 45.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-03-06
Primary completion date: 2023-12-01
Completion date: 2023-12-01
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT05323019: Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression
Official title: A Randomized, Controlled, Single-Blind, Phase 2 Study in Treatment Resistant Major Depressive Disorder Patients Receiving Intranasal Esketamine (SpravatoTM) Over a 28-day Period Comparing Addition of Almond TherapyTM With Treatment-as-Usual
Acronym: ZYL-730-01
Sponsor: Zylorion Health (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Funding
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-13
Primary completion date: 2023-02-01
Completion date: 2023-02-01
Plan to share individual participant data: YES
IPD sharing description: IPD will be available to other members of the research team including Dr. Craig Buchholz
IPD time frame: Throughout the study.
IPD access criteria: Involved in data collection
Clinical trial NCT04530604: Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
Official title: Defibrotide Therapy for SARS-CoV2 Acute Respiratory Distress Syndrome (ARDS)
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-01
Primary completion date: 2021-03-26
Completion date: 2021-04-09
Plan to share individual participant data: NO
Clinical trial NCT03740243: Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology
Official title: Comparison of Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology
Sponsor: Stony Brook University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: No enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-30
Primary completion date: 2020-03-22
Completion date: 2020-03-22
Plan to share individual participant data: NO
IPD sharing description: In regards to the participants and neonates' health information, care will be taken to ensure privacy. All data and specimens will be coded with a case number and de-identified, and exported to a REDcap application system (secure data file approved by Institutional Review Board). The REDcap application data will be kept on the department's secure, shared institutional, server space.
Clinical trial NCT03485053: A Single Ascending Study of IOP Injection in Patients With Iron Deficient Anemia
Official title: 2 Part, Phase II Study of Intravenous, Single Ascending Dose Administrations of IOP Injection in Patients With Iron Deficient Anemia
Sponsor: MegaPro Biomedical Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor terminate the trial and will conduct a phase 2b clinical trial further
Enrollment: 49.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-29
Primary completion date: 2020-09-30
Completion date: 2021-08-31
Plan to share individual participant data: NO
Clinical trial NCT04650399: A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
Official title: A Multicenter, Randomized, Controlled, Double Blinded Pivotal Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Adolescents Aged 12 Years to <18 Years
Sponsor: Butantan Institute (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 750.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-31
Primary completion date: 2023-02-13
Completion date: 2024-02-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05295394: Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study
Official title: Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study
Acronym: PADDLE184V
Sponsor: Fundación Huésped (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Low recruitment, We did not find participants with the M184V mutation , inclusion criteria , throughout 230 resistance tests carried out
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-05-22
Primary completion date: 2022-08-31
Completion date: 2022-08-30
Plan to share individual participant data: YES
IPD sharing description: to publish week 48 study results
IPD time frame: 3 month after last patient last visit
Clinical trial NCT04768010: Misoprostol for Bloating and Distension
Official title: Misoprostol for the Management of Bloating and Gaseous Distension in Patients With Cirrhosis: an Open Label Trial
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: After significant delays study was never initiated. No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-08-31
Primary completion date: 2023-09-18
Completion date: 2023-09-18
Plan to share individual participant data: NO